Via libera dell’FDA per le forme recidivanti di sclerosi multipla Negli Stati Uniti, la Food and Drug Administration (FDA) ha approvato diroximel fumarato, farmaco sviluppato da Biogen, per il trattamento di forme recidivanti di sclerosi…
2 Dicembre 2019
Il sito Neurologia Italiana è una testata registrata presso il Tribunale di Milano, 111 del 5/10/2020
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.